Publications by the researcher in collaboration with Rocio Gonzalez-Conejero Hilla (23)

2022

  1. MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction

    Journal of Personalized Medicine, Vol. 12, Núm. 7

2020

  1. Pilot study on the role of circulating mirnas for the improvement of the predictive ability of the 2mace score in patients with atrial fibrillation

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-11

2018

  1. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6

2015

  1. CALU polymorphism A29809G affects calumenin availability involving vascular calcification

    Journal of Molecular and Cellular Cardiology, Vol. 82, pp. 218-227

2014

  1. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation

    Thrombosis and Haemostasis, Vol. 112, Núm. 4, pp. 781-788

2010

  1. Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy

    Thrombosis Research, Vol. 126, Núm. 1

  2. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction

    Thrombosis and Haemostasis

2009

  1. Antithrombin Cambridge ll (A384S) supports a role for antithrombin deficiency in arterial thrombosis

    Thrombosis and Haemostasis, Vol. 101, Núm. 3, pp. 483-486

  2. Implications of pharmacogenetics for oral anticoagulants metabolism

    Current Drug Metabolism, Vol. 10, Núm. 6, pp. 632-642

  3. Pharmacogenetics in Cardiovascular Antithrombotic Therapy

    Journal of the American College of Cardiology, Vol. 54, Núm. 12, pp. 1041-1057

2008

  1. Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk

    Annals of Medicine, Vol. 40, Núm. 7, pp. 553-559

2007

  1. Prognostic value of annexin A5-1 C/T polymorphism in a long term follow-up after premature myocardial infarction [2]

    Journal of Thrombosis and Haemostasis

  2. The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 8, pp. 1701-1706

2006

  1. Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated

    Future Cardiology, Vol. 2, Núm. 2, pp. 197-203

2005

  1. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction

    Journal of the American College of Cardiology, Vol. 45, Núm. 1, pp. 25-29

  2. Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction

    Haematologica, Vol. 90, Núm. 3, pp. 421-423

  3. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction

    Thrombosis and Haemostasis, Vol. 94, Núm. 6, pp. 1294-1299

2004

  1. Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol [3]

    Journal of Thrombosis and Haemostasis

  2. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation

    Journal of Molecular and Cellular Cardiology, Vol. 37, Núm. 3, pp. 699-704

  3. Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction

    American Heart Journal, Vol. 148, Núm. 4, pp. 602-605